– UK, London – Hikma Pharmaceuticals PLC (LON: HIK | DIFX: HIK) today announced the appointment of Dr. Deneen Vojta (M.D.) to its Board as an Independent Non-Executive Director, effective 1 November 2022.
“I am delighted to welcome Deneen to the Hikma Board, ‘Deneen is a seasoned healthcare executive and medical professional with extensive experience working in large, international, high-growth organisations across the entire spectrum of the healthcare system. She brings to the Board experience as both an entrepreneur and a strategic leader in the healthcare industry.” said Executive Chairman and CEO, Said Darwazah.
About Dr. Deneen Vojta
Deneen is President of Health Solutions and Innovation at Turning Point Healthcare Solutions, a specialty case management services and technologies provider. Before this, she was EVP for Research and Development at UnitedHealth Group, where she was responsible for building new businesses and creating innovative payment and delivery system frameworks. She was also the Founder and CEO of MYnetico, a digital weight management platform acquired by UHG in 2006. Earlier, she served as CMO of ARIA Health Care System and Health Partners of Philadelphia.
Deneen is currently a Non-Executive Director of Sensei Biotherapeutics, Workit Health, and Children’s Minnesota.
For more information: https://www.hikma.com/home/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
